Continuous Infusion Versus Intermittent IV Bolus of Cefazolin: Prevention of Surgical Site Infection During CABG Surgeries in Egyptian Patients.

NCT07658378 | Not Yet Recruiting Phase 4 DMC

• 1 other identifier: 08112025
• Study Type: interventional
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

A randomized controlled trial on adults who underwent coronary artery bypass grafting (CABG) surgery. To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing surgical site infection in the CABG population. Eligible patients will be randomized using a block design into 2 groups: intervention and control. The intervention group will use continuous infusion of cefazolin (CI), while the control group will follow the traditional presurgical prophylaxis protocol of intermittent cefazolin doses (INT).

Conditions

Surgical Site Infection (SSI)

Keywords

cefazolin; continuous infusion; intermittent; surgical site infection; surgical prophylaxis; CABG

Outcome Measures

Primary Outcomes (1)

• Incidence of SSI

  Within 3 months after surgery

Study Arms (2)

Intraoperative continuous infusion (CI) of cefazolin

EXPERIMENTAL

Drug: Cefazolin 2 g Infusion

Intermittent (INT) cefazolin

ACTIVE COMPARATOR

Drug: Cefazolin 2 GM Injection

Interventions

Cefazolin 2 g Infusion DRUG

To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing SSIs in a CABG (coronary artery bypass grafting) population.

Intraoperative continuous infusion (CI) of cefazolin

Cefazolin 2 GM Injection DRUG

To evaluate the effectiveness of intermittent (INT) cefazolin administration in preventing SSIs in a CABG (coronary artery bypass grafting) population.

Intermittent (INT) cefazolin

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Cardiothoracic ICU-admitted patients who underwent CABG on CPB.

You may not qualify if:

• Patients who require reoperation within 30 days.
• Immunosuppressant patients.
• Patients who are not adherent to the protocol time or dosing, either preoperatively, during, or postoperatively.
• Pregnancy or breastfeeding.
• Patients who refused to sign the informed consent.

Sponsors & Collaborators

• Helwan University: lead

MeSH Terms

Conditions

Surgical Wound Infection

Interventions

Cefazolin

Condition Hierarchy (Ancestors)

Wound Infection; Infections; Postoperative Complications; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Cephalosporins; beta-Lactams; Lactams; Amides; Organic Chemicals; Thiazines; Sulfur Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Central Study Contacts

Heba A Abdeen

CONTACT

0201003403231; hebabdeen89@gmail.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: June 13, 2026
• First Posted: June 22, 2026
• Study Start: July 1, 2026
• Primary Completion (Estimated): September 30, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: June 24, 2026

Record last verified: 2026-06